Company Profile
Nexvet Biopharma public limited company and its subsidiaries (the “Company”) is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics. Biologics are therapeutic proteins derived from biological sources. As a class, biologics have transformed human medicine in recent decades and represent many of the top-selling therapies on the market today. The Company’s platform technology, which it refers to as “PETization,” is an algorithmic approach that enables the Company to rapidly create monoclonal antibodies (“mAbs”) a type of biologic, that are designed to be recognized as “self” or “native” by an animal’s immune system, a property referred to as “100% species-specificity.” PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to cre... more >
Recent Newsmore >
04 November 2016Nexvet Reports Financial Results for First Quarter of Fiscal Year 2017
DUBLIN, Ireland, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three month period ended September 30, 2016. Recent highlights include: Advanced preparations for pivotal studies of the anti-NGF mAb therapy frunevetmab for cats and a pivotal safety study of the anti-NGF mAb therapy ranevetmab for dogs Initiated a pivotal target animal safety study of frunevetmab in October Announced publication of two peer-reviewed ar... 
19 October 2016Nexvet to Present at the 25th Annual Credit Suisse Healthcare Conference
DUBLIN, Ireland, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the 25th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ on Monday, November 7th at 11:00AM MT. Dr. Heffernan will provide an overview of Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, as well as its therapies in development in the ... 
02 September 2016Nexvet Biopharma Reports Full Year Fiscal 2016 Results
DUBLIN, Ireland, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced financial results for its 2016 fiscal year, which concluded on June 30, 2016. Corporate Highlights: Announced positive data from a multi-center, placebo-controlled, randomized, double-blind pivotal efficacy and field safety study of ranevetmab (or ‘NV-01’), which enrolled 262 dogs with naturally occurring osteoarthritis and met its primary endp... 
20 July 2016Nexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference
DUBLIN, Ireland, July 20, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced the recent publication of two peer-reviewed papers regarding frunevetmab in the Journal of Veterinary Internal Medicine (JVIM), as well as an upcoming presentation by Nexvet’s Chief Scientific Officer Dr. David Gearing at the Veterinary Pain Short Course in San Diego, California on July 29, 2016. Frunevetmab (“NV-02”) is Nexvet’s anti-nerve growth facto... 
Featured Items
There are currently no items available.
Stock Quotemore >
Exchange :NASDAQ
Price :$4.50
Change : Stock is Up 0.09 (2.04%)
Volume :5,925
Data as of 12/09/16 3:59 p.m. ET
Minimum 20 minute delay
Receive Email AlertsE-mail Alert Icon
Sign up to receive email alerts whenever Nexvet Biopharma plc posts new information to the site. Just enter your email address and click Submit.

Data Provided by Thomson Reuters

Nexvet Biopharma

Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522

Level 8, 31 Queen Street
Melbourne 3000
P: +61 (3) 9610 4400

United States
275 Post Street
4th Floor
San Francisco, CA 94108